

6. Literaturverzeichnis

1. Aiello, S., Noris, M., Remuzzi, G. (1999): Nitric oxide/L-arginine in uremia. *Miner. Electrolyte Metab.* **25**:384–390.
2. Aiello, S., Remuzzi, G., Noris, M. (1998): Nitric oxide/endothelin balance after nephron reduction. *Kidney Int. Suppl.* **65**:S63–S67.
3. Akyurek, L.M., et al. (1996): Inducible and endothelial nitric oxide synthase expression during development of transplant arteriosclerosis in rat aortic grafts. *Am. J. Pathol.* **149**:1981–1990.
4. Alderton, W. K., Cooper, C.E. Knowles R.G. (2001): Nitric oxide synthases: structure, function and inhibition. *Biochem. J.*; **357**: 593 – 615.
5. Andrew, P.J., Mayer, B. (1999). Enzymatic function of nitric oxide synthases. *Cardiovasc. Res.* **43**:521–531.
6. Balla G., Jacob H.S. et al. (1992): Ferritin: a cytoprotective antioxidant strategem of endothelium. *J Biol Chem*; **267(25)**: 18148 - 18153.
7. Bath, P.M. (1993): The effect of nitric oxide-donating vasodilators on monocyte chemotaxis and intracellular cGMP concentrations in vitro. *Eur. J. Clin. Pharmacol.* **45**:53–58.
8. Beasley, D., Schwartz, J.H., Brenner, B.M. (1991). Interleukin 1 induces prolonged L-arginine-dependent cyclic guanosine monophosphate and nitrite production in rat vascular smooth muscle cells. *J. Clin. Invest.* **87**:602–608.
9. Behr-Roussel, D., Rupin, A. et al. (2000): Histochemical evidence for inducible nitric oxide synthase in advanced but non-ruptured human atherosclerotic carotid arteries. *Histochem. J.* **32**:41–51.
10. Binder, C.J., et al. (2002): Innate and acquired immunity in atherogenesis. *Nat. Med.* **8**:1218–1226.
11. Cayatte AJ, Palacino JJ, et al. (1994): Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. *Arterioscleros Thromb* **14**:753 – 759.
12. Clark, R.S., et al. (1996): Inducible nitric oxide synthase expression in cerebrovascular smooth muscle and neutrophils after traumatic brain injury in immature rats. *Pediatr. Res.* **39**:784–790.

13. Collins, T. (1993). Endothelial nuclear factor-kappa B and the initiation of the atherosclerotic lesion. *Lab. Invest.* **68**:499–508.
14. Cooke J.P., Singer A.H. et al. (1992): Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. *J Clin Invest*; **90(3)**: 1168–1172.
15. Cornwell, T.L., Arnold, E. et al. (1994): Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMPdependent protein kinase by cGMP. *Am. J. Physiol.* **267**:C1405–C1413
16. Cross J.(2002): Endothelial Dysfunction in Uraemia. *Blood Purif* **20**:459–461
17. Daugirdas, J.T. (1990): Rapid methods of estimating Kt/V: three formulas compared. *ASAIO Trans.* **36**:M362–M364.
18. Daugirdas, J.T. (1995): Simplified equations for monitoring Kt/V, PCRn, eKt/V, and ePCRn. *Adv. Ren. Replace. Ther.* **2**:295–304.
19. Davignon J., Ganz P. (2004): Role of Endothelial Dysfunction in Atherosclerosis *Circulation* **109 Suppl III**: III-27 – III-32.
20. De Caterina, R., et al. (1995). Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. *J. Clin. Invest.* **96**:60–68.
21. Descamps – Latscha B, Drüeke T, Witko – Sarsat V (2001): Dialysis induced oxidative stress: Biological aspects, clinical consequences and therapy. *Semin Dial* **14(3)**: 193 – 199.
22. Dumont, Y., D'Amours, M., et al. (2001): Supplementation with a low dose of L-arginine reduces blood pressure and endothelin-1 production in hypertensive uraemic rats. *Nephrol. Dial. Transplant.* **16**:746–754.
23. Eiserich, J.P., et al. (1998): Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. *Nature.* **391**:393–397.
24. Endemann D.H., Schiffrin E.L. (2004): Endothelial Dysfunction. *J Am Soc Nephrol* **15**: 1983–1992.
25. Endemann D.H., Schiffrin E.L. (2004): Endothelial Dysfunction. *J Am Soc Nephrol* **15**: 1983 – 1992.
26. Fliser D. (2005): Asymmetric dimethylarginine (ADMA): the silent transition from an 'uraemic toxin' to a global cardiovascular risk molecule. *Eur J Clin Invest*; **35**: 71 – 79.

27. Floege, J., et al. (1992): Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. *Kidney Int.* **41**:297–309.
28. Foley R.N., Parfrey P.S., Sarnak M.J.(1998): Cardiovascular disease in chronic renal disease: Clinical epidemiology of cardiovascular disease in chronic renal disease. *Am J Kid Dis*; **32**: S112 – S119
29. Fukuo, K., et al. (1996): Nitric oxide induces upregulation of Fas and apoptosis in vascular smooth muscle. *Hypertension.* **27**:823–826.
30. Furchgott, R.F., Zawadzki J.V. (1980): The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. *Nature*; **288**: 373 - 376.
31. Garg U.C., Haasid A. (1989 A): Nitric oxide generating vasodilators and 8- bromo – cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells *J Clin Invest*, **83**: 1774 – 1777
32. Garg, U.C., Hassid, A. (1989 B): Inhibition of rat mesangial cell mitogenesis by nitric oxide-generating vasodilators. *Am. J. Physiol.***257**:F60–F66.
33. Gewaltig M.T., Kojda G. (2002): Vasoprotection by nitric oxide: mechanisms and therapeutic potential. *Cardiovasc Res*; **55**: 250 – 260.
34. Gewaltig, M.T., Kojda, G. (2002). Vasoprotection by nitric oxide: mechanisms and therapeutic potential. *Cardiovasc. Res.* **55**:250–260.
35. Giulietti A., Overbergh L. et al. (2001): An Overview of Real – time quantitative PCR: Applications to quantify cytokine gene expression. *Methods*; **25**: 386 – 401.
36. Gupta, A., Robinson, K. (1997): Hyperhomocysteinaemia and end stage renal disease. *J. Nephrol.* **10**:77–84.
37. Hattori, Y., Matsumura, M., Kasai, K. (2003): Vascular smooth muscle cell activation by C-reactive protein. *Cardiovasc. Res.* **58**:186–195.
38. Hazen, S.L., et al. (1999): Formation of nitric oxide-derived oxidants by myeloperoxidase in monocytes: pathways for monocyte-mediated protein nitration and lipid peroxidation in vivo. *Circ. Res.* **85**:950–958.
39. Hecker, M., Cattaruzza, M., Wagner, A.H. (1999): Regulation of inducible nitric oxide synthase gene expression in vascular smooth muscle cells. *Gen. Pharmacol.* **32**:9–16.

40. Herzog C.A., Ma J.Z., Collins A.J. (1998): Poor long term survival after acute myocardial infarction among patients on long – term dialysis. *NEJM*; **339**: 799-805
41. Huang C – J., Haque I.U. et al (2002): Environmental pH regulates LPS – induced nitric oxide formation in murine macrophages. *Nitric Oxide*; **6 (1)**: 73 – 78.
42. Hunter, G.C., et al. (1999): The contribution of inducible nitric oxide and cytomegalovirus to the stability of complex carotid plaque. *J. Vasc. Surg.* **30**:36–49.
43. Ikizler T.A. (2002): Epidemiology of vascular disease in renal failure. *Blood Purif* **20**: 6 - 10
44. Ito, S. (1995): Nitric oxide in the kidney. *Curr. Opin. Nephrol. Hypertens.* **4**:23–30.
45. Jankowski J, Van der Giet M et al (2003): Increased plasma phenylacetic acid in patients with end – stage renal failure inhibits iNOS expression. *J Clin Invest* **112**: 256 – 264.
46. Jankowski, J, Luftmann, H. et al. (1998): Characterization of dimethylguanosine, phenylethylamine, and phenylacetic acid as inhibitors of Ca²⁺ ATPase in end-stage renal failure. *J Am Soc Nephrol*; **9**: 1249 - 57.
47. Katsuyama, K., Shichiri, M. et al. (1998): NO inhibits cytokine-induced iNOS expression and NF-kappaB activation by interfering with phosphorylation and degradation of I kappa B-alpha. *Arterioscler. Thromb. Vasc. Biol.* **18**:1796–1802.
48. Ketteler, M., Border, W.A., Noble, N.A. (1994): Cytokines and L-arginine in renal injury and repair. *Am. J. Physiol.* **267**:F197–F207.
49. Kielstein, J., Frölich J. et al. (2001): ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patients with renal disease? *Nephrol Dial Transplant* **16**: 1742-1745
50. Kone B.C., Kuncewicz, T. et al. (2003): Protein interactions with nitric oxide synthases: controlling the right time, the right place, and the right amount of nitric oxide. *Am J Physiol Renal Physiol* **285**: F178–F190.
51. Kubes, P., Suzuki, M., Granger, D.N. (1991): Nitric oxide: an endogenous modulator of leukocyte adhesion. *Proc. Natl. Acad. Sci. U. S. A.* **88**:4651–4655.
52. Kuhlencordt, P.J., Chen, J. et al. (2001): Genetic deficiency of inducible nitric oxide synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice. *Circulation.* **103**:3099–3104.

53. Lee, L.K., Meyer, T.W. et al. (1995): Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney. *J. Clin. Invest.* **96**:953–964.
54. Leeuwenburgh, C., et al. (1997): Reactive nitrogen intermediates promote low density lipoprotein oxidation in human atherosclerotic intima. *J. Biol. Chem.* **272**:1433–1436.
55. Li, A.C., Glass, C.K. (2002): The macrophage foam cell as a target for therapeutic intervention. *Nat. Med.* **8**:1235–1242.
56. Lindner A, Charra B, et al. (1974): Accelerated atherosclerosis in prolonged maintenance hemodialysis. *N Engl J Med*; **290**: 697–702.
57. London G.M. (2001): Vascular Disease and Atherosclerosis in Uremia. *Blood Purif*; **19**:139–142.
58. London, G.M., Drueke, T.B. (1997): Atherosclerosis and arteriosclerosis in chronic renal failure. *Kidney Int.* **51**:1678–1695.
59. Lonnemann, G. (1998): Assessment of the quality of dialysate. *Nephrol. Dial. Transplant.* **13**(Suppl.):17–20.
60. Luoma J., Ylä – Herrtuala S. (1999): Expression of inducible nitric oxide synthase in macrophages and smooth muscle cells in various types of human atherosclerotic lesions *Virchows Arch*; **434**: 561 – 568.
61. MacAllister, R.J., Whitley, G.S., Vallance, P. (1994): Effects of guanidino and uremic compounds on nitric oxide pathways. *Kidney Int.* **45**:737–742.
62. Mellion, B.T., et al. (1981): Evidence for the inhibitory role of guanosine 3', 5'-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. *Blood.* **57**:946–955.
63. Moeslinger, T., Spieckermann, P.G. (2001): Urea-induced inducible nitric oxide synthase inhibition and macrophage proliferation. *Kidney Int.* **78**(Suppl.):S2–S8.
64. Moncada S., Higgs A. (1993): The L - Arginine – nitric oxide pathway. *N Engl J Med.*; **329** (27): 2002 – 12.
65. Moncada, S., and Higgs, E.A. 1995. Molecular mechanisms and therapeutic strategies related to nitric oxide. *FASEB J.* **9**:1319–1330.
66. Morrissey, J.J., et al. (1994): Location of an inducible nitric oxide synthase mRNA in the normal kidney. *Kidney Int.* **45**:998–1005.
67. Naseem K.M. (2005): The role of nitric oxide in cardiovascular diseases. *Mol Asp Med* **26**: 33 – 65

68. Nathan, C., Xie, Q.W. (1994): Nitric oxide synthases: roles, tolls, and controls. *Cell*. **78**:915–918.
69. Oberdoerster, J., Guizzetti, M., Costa, L.G. (2000): Effect of phenylalanine and its metabolites on the proliferation and viability of neuronal and astroglial cells: possible relevance in maternal phenylketonuria. *J. Pharmacol. Exp. Ther.* **295**:295–301.
70. Overbergh, L., Valckx, D. et al. (1999): Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. *Cytokine*. **11**:305–312.
71. Pahan K, Sheikh FG et al. (1997): Lovastatin and Phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia and macrophages. *J Clin Invest* **100 (11)**: 2671 – 2679.
72. Passauer, J., Bussemaker, E., et al (2000): Evidence in vivo showing increase of baseline nitric oxide generation and impairment of endothelium-dependent vasodilation in normotensive patients on chronic hemodialysis. *J. Am. Soc. Nephrol.* **11**:1726–1734.
73. Raine, A.E., et al. (1992) : Report on management of renal failure in Europe, XXII, 1991. *Nephrol. Dial. Transplant.* **7**(Suppl):7–35.
74. Recalcati S., Taramelli D. et al. (1998): Nitric Oxide-Mediated Induction of Ferritin Synthesis in J774 Macrophages by Inflammatory Cytokines: Role of Selective Iron Regulatory Protein-2 Downregulation. *Blood*; **91 (3)**: 1059 – 1066.
75. Rikitake Y., Hirata K – I et al. (1998): Inhibitory effect of inducible type nitric oxide synthase on oxidative modification of low – density lipoprotein by vascular smooth muscle cells. *Atherosclerosis*; **136**: 51 – 57.
76. Rösen P. (2002): Endotheliale Dysfunktion: ein Synonym für funktionelle Atherosklerose. *J Kardiol* **9**: 556 – 62.
77. Russell, M.E., Wallace, A.F. et al (1995): Upregulation and modulation of inducible nitric oxide synthase in rat cardiac allografts with chronic rejection and transplant arteriosclerosis. *Circulation*. **92**:457–464.
78. Savage T., Clarke A.L., et al. (1998) : Calcified plaque is common in the carotid and femoral arteries of dialysis patients without clinical vascular disease. *Nephrol Dial Transplant*; **13**: 2004 – 2012.
79. Tepel M (2003): Oxidative stress: does it play a role in the genesis of essential hypertension and hypertension of uraemia? *Nephrol Dial Transplant* **18**: 1439–1442.

80. Tepel M, Echelmeyer M. et al (2000): Increased intracellular reactive oxygen species in patients with end – stage renal failure: Effect of hemodialysis. *Kid Int*; **58(2)**:867
81. Tepel, M., et al. (1995) : Lymphocytic Na(+)-H+ exchange increases after an oral glucose challenge. *Circ. Res.* **77**:1024–1029.
82. Thuraisingham R.C., Roberts N.B. et al. (2002): Altered L-arginine metabolism results in increased nitric oxide release from uraemic endothelial cells. *Clinical Science* **103**: 31–41.
83. Thuraisingham R.C., Yaqoob M.M.(2003): Oxidative consumption of nitric oxide: A potential mediator of uremic vascular disease *Kid Int* **63, suppl 84**: S29 – S32
84. US Renal Data System (1997): Excerpts from the USRDS 1997 Annual Data Report. *Am J Kid Dis* **30**: S1 – S195
85. Vallance, P., Leone, A., et al. (1992): Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. *Lancet.* **339**:572–575.
86. Vanholder R., De Smet R., et al. (2003 A): Review on uremic toxins: classification, concentration, and interindividual variability. *Kidney Int*; **63**:1934 – 1943.
87. Vanholder R., Glorieux G., et al. (2003 B): New insights in uremic toxins. *Kidney Int Suppl*: S6 – 10.
88. Villaschi S. Spagnoli LG (1983): Autoradiographic and ultrastructural studies on the human fibro - atheromatous plaque. *Atherosclerosis* **48**: 95 – 100.
89. Wheeler, M.A., Smith, S.D. et al. (1997): Effect of long-term oral L-arginine on the nitric oxide synthase pathway in the urine from patients with interstitial cystitis. *J. Urol.* **158**:2045–2050.
90. Wilcox, J.N., et al. (1997): Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. *Arterioscler. Thromb. Vasc. Biol.* **17**:2479–2488.
91. Wu, G., Flynn N.E. et al. (1999) : Dietary protein or arginine deficiency impairs constitutive and inducible nitric oxide synthesis by young rats. *J. Nutr.*; **129 (7)**: 1347 – 1354.
92. Xie QW, Kashiwabara Y et al. (1994): Role of transcription factor NF – κ B /Rel in the induction of nitric oxide synthase. *J. Biol. Chem.* **269**: 4705 – 4708

- 93.** Yan, Z.Q., Yokota, T. et al (1996): Expression of inducible nitric oxide synthase inhibits platelet adhesion and restores blood flow in the injured artery. *Circ. Res.* **79**:38–44.